Actavis recalls pills made by Patheon

Allergan ($AGN), which this month completed the sale of its Actavis generics unit to Teva ($TEVA), is still cleaning up Actavis business, like the recall of tens of thousands of bottles of a diabetes drug.

According to the most recent FDA Enforcement Report, the drugmaker is recalling 5 lots, consisting of 167,152 bottles, of Glipizide, a treatment for Type 2 diabetes. The class II recall began after stability testing determined the drugs exceeded dissolution specification rates for the 10-hour testing point. The product was made for Actavis by contractor Patheon.

Actavis has had some problems with contractors recently. The Dublin-based company earlier this year voluntarily recalled 447,150 bottles, of ciprofloxacin ophthalmic solution that was manufactured by Hi-Tech Pharmacal, a unit of Lake Forest, IL-based Akorn ($AKRX).

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Earlier this month, Allergan completed the sale of Actavis to Teva for $40 billion. Israel-based Teva, the largest generics maker in the word, also agreed to buy Actavis U.S. distribution unit, Anda, for another $500 million. With the deal, Teva CEO Erez Vigodman has pledged to increase the drug company’s revenue by as much as 40% by 2019.

- access the recall here  

Related Articles: 
Akorn's Hi-Tech is the source of large Actavis recall  
Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug
Teva wants Allergan's distribution biz now that $40B drug deal has closed

Read more on

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.